KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Amneal Pharmaceuticals (AMRX) Leases (2019 - 2025)

Amneal Pharmaceuticals has reported Leases over the past 7 years, most recently at $54.0 million for Q4 2025.

  • Quarterly results put Leases at $54.0 million for Q4 2025, up 27.62% from a year ago — trailing twelve months through Dec 2025 was $54.0 million (up 27.62% YoY), and the annual figure for FY2025 was $54.0 million, up 27.62%.
  • Leases for Q4 2025 was $54.0 million at Amneal Pharmaceuticals, up from $31.8 million in the prior quarter.
  • Over the last five years, Leases for AMRX hit a ceiling of $67.5 million in Q1 2021 and a floor of $10.4 million in Q1 2025.
  • Median Leases over the past 5 years was $37.7 million (2022), compared with a mean of $42.0 million.
  • Biggest five-year swings in Leases: tumbled 71.73% in 2022 and later skyrocketed 75.18% in 2023.
  • Amneal Pharmaceuticals' Leases stood at $60.4 million in 2021, then decreased by 7.04% to $56.1 million in 2022, then dropped by 22.88% to $43.3 million in 2023, then fell by 2.15% to $42.4 million in 2024, then increased by 27.62% to $54.0 million in 2025.
  • The last three reported values for Leases were $54.0 million (Q4 2025), $31.8 million (Q3 2025), and $17.7 million (Q2 2025) per Business Quant data.